Printer Friendly

XOMA'S E5 PRODUCT SUBMITTED FOR APPROVAL IN JAPAN

 BERKELEY, Calif., Oct. 19 /PRNewswire/ -- XOMA Corp. (NASDAQ-NMS: XOMA) today announced that its E5(R) anti-endotoxin monoclonal antibody product has been submitted for marketing approval in Japan. This marks the first filing for regulatory approval in Japan of an anti-endotoxin monoclonal antibody.
 The E5 application was submitted by Pfizer Japan. Pfizer Inc. (NYSE: PFE) is XOMA's development and marketing partner for E5. If approved by the Ministry of Health and Welfare's Koseisho, E5 will be marketed in Japan by Pfizer. The filing was based on preclinical and clinical testing conducted in Japan with supplemental data supplied by XOMA.
 "This filing is an important step forward in our worldwide efforts to commercialize E5," said XOMA Chairman and Chief Executive Officer John L. Castello. "We applaud the excellent work of the professionals at Pfizer Japan who prepared the filing, and the many people here at XOMA who contributed to it."
 E5 is a monoclonal antibody that targets endotoxin, the toxic portion of the cell wall of gram-negative bacteria. Endotoxin plays a central role in gram-negative sepsis, a condition which can occur following abdominal trauma, or as a complication of surgery, urinary tract infections or a weakened immune system. Over 200,000 cases of gram-negative sepsis occur each year in the United States, leading to approximately 70,000 deaths, according to data compiled by the Centers for Disease Control and Prevention.
 XOMA is a biotechnology company engaged in the development of pharmaceutical products based on recombinant DNA and other technologies for the treatment of infectious and immune system diseases and other serious disorders.
 -0- 10/19/93
 /CONTACT: Carol D. DeGuzman of XOMA, 510-644-1170/
 (XOMA PFE)


CO: XOMA Corp.; Pfizer Inc. ST: California IN: MTC SU: PDT

PK-BR -- SF009 -- 3938 10/19/93 11:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 19, 1993
Words:293
Previous Article:MCLATCHY NEWSPAPERS REPORTS THIRD QUARTER EARNINGS
Next Article:BEARINGS, INC. DECLARES DIVIDEND
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters